Aileron Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

James Windsor

Chief executive officer

US$511.5k

Total compensation

CEO salary percentage	16.7%
CEO tenure	less than a year
CEO ownership	0.04%
Management average tenure	no data
Board average tenure	5.6yrs

Recent management updates

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

CEO Compensation Analysis

How has James Windsor's remuneration changed compared to Aileron Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$512k	US$85k	-US$16m

Compensation vs Market: James's total compensation ($USD511.55K) is about average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Insufficient data to compare James's compensation with company performance.

CEO

James Windsor (56 yo)

less than a year

Tenure

US$511,546

Compensation

Dr. James Brian Windsor, Ph.D. had been a Director of TFF Pharmaceuticals, Inc. since January 2018 until March 21, 2022 and served as its Chief Science Officer since September 2019 until March 21, 2022. Dr...

Board Members

Name	Position	Tenure	Compensation	Ownership
James Windsor	CEO & Director	less than a year	US$511.55k	0.043% $ 34.9k
Josef von Rickenbach	Independent Chairman	4.8yrs	US$67.97k	0.13% $ 105.8k
Alan Musso	Independent Director	less than a year	no data	0% $ 0
Carol Prives	Member of Scientific Advisory Board	6.1yrs	no data	no data
Brian Druker	Member of Scientific Advisory Board	6.1yrs	no data	no data
Alan List	Member of Scientific Advisory Board	6.1yrs	no data	no data
Reinhard Ambros	Independent Lead Director	10.8yrs	US$46.25k	0.0017% $ 1.4k
William Fairey	Independent Director	less than a year	US$9.38k	0% $ 0
Manuel Aivado	Director	5.6yrs	US$630.74k	0.00029% $ 233.8
Ulrich Steidl	Member of Scientific Advisory Board	no data	no data	no data

5.6yrs

Average Tenure

64yo

Average Age

Experienced Board: ALRN's board of directors are considered experienced (5.6 years average tenure).

Aileron Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age